CA2268353A1 - Vecteurs alphavirus et retrovirus - Google Patents

Vecteurs alphavirus et retrovirus Download PDF

Info

Publication number: CA2268353A1
Authority: CA; Canada
Prior art keywords: retrovirus; rna; alphavirus; recombinant; cells
Prior art date: 1996-10-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002268353A

Other languages

English (en)

Inventor

Henrik Garoff

Kejun Li

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-10

Filing date

1997-10-10

Publication date

1998-04-16

1996-10-10 Priority claimed from SE9603702A external-priority patent/SE9603702D0/xx

1997-07-03 Priority claimed from SE9702585A external-priority patent/SE9702585D0/xx

1997-10-10 Application filed by Individual filed Critical Individual

1998-04-16 Publication of CA2268353A1 publication Critical patent/CA2268353A1/fr

Status Abandoned legal-status Critical Current

Links

239000013598 vector Substances 0.000 title claims abstract description 127
241001430294 unidentified retrovirus Species 0.000 claims abstract description 179
108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 137
210000004027 cell Anatomy 0.000 claims abstract description 128
108090000623 proteins and genes Proteins 0.000 claims abstract description 85
230000014509 gene expression Effects 0.000 claims abstract description 54
241000710929 Alphavirus Species 0.000 claims abstract description 49
238000004519 manufacturing process Methods 0.000 claims abstract description 37
208000015181 infectious disease Diseases 0.000 claims abstract description 25
230000002458 infectious effect Effects 0.000 claims abstract description 22
101710172711 Structural protein Proteins 0.000 claims abstract description 17
108091092195 Intron Proteins 0.000 claims abstract description 9
108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 7
210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 6
229940088623 biologically active substance Drugs 0.000 claims abstract 2
241000710961 Semliki Forest virus Species 0.000 claims description 103
239000002245 particle Substances 0.000 claims description 98
108020004414 DNA Proteins 0.000 claims description 51
230000010076 replication Effects 0.000 claims description 20
238000011534 incubation Methods 0.000 claims description 18
238000000034 method Methods 0.000 claims description 17
102000004169 proteins and genes Human genes 0.000 claims description 17
102000053602 DNA Human genes 0.000 claims description 12
108091027544 Subgenomic mRNA Proteins 0.000 claims description 11
102000004190 Enzymes Human genes 0.000 claims description 10
108090000790 Enzymes Proteins 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
239000002243 precursor Substances 0.000 claims description 9
238000010361 transduction Methods 0.000 claims description 9
230000026683 transduction Effects 0.000 claims description 9
238000001890 transfection Methods 0.000 claims description 9
238000001415 gene therapy Methods 0.000 claims description 8
238000000338 in vitro Methods 0.000 claims description 6
238000003780 insertion Methods 0.000 claims description 6
230000037431 insertion Effects 0.000 claims description 6
210000005260 human cell Anatomy 0.000 claims description 5
108700009124 Transcription Initiation Site Proteins 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 4
108010052285 Membrane Proteins Proteins 0.000 claims description 3
102000018697 Membrane Proteins Human genes 0.000 claims description 3
241000714177 Murine leukemia virus Species 0.000 claims description 3
210000004102 animal cell Anatomy 0.000 claims description 3
230000000295 complement effect Effects 0.000 claims description 3
241000710960 Sindbis virus Species 0.000 claims description 2
241000251468 Actinopterygii Species 0.000 claims 1
241001128034 Amphotropic murine leukemia virus Species 0.000 claims 1
241000271566 Aves Species 0.000 claims 1
241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
206010066919 Epidemic polyarthritis Diseases 0.000 claims 1
241000238631 Hexapoda Species 0.000 claims 1
241000710942 Ross River virus Species 0.000 claims 1
241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 1
241000710951 Western equine encephalitis virus Species 0.000 claims 1
210000000805 cytoplasm Anatomy 0.000 abstract description 13
230000001086 cytosolic effect Effects 0.000 abstract description 3
108010027225 gag-pol Fusion Proteins Proteins 0.000 description 40
239000013612 plasmid Substances 0.000 description 35
239000012634 fragment Substances 0.000 description 32
238000004806 packaging method and process Methods 0.000 description 21
102000039446 nucleic acids Human genes 0.000 description 19
108020004707 nucleic acids Proteins 0.000 description 19
150000007523 nucleic acids Chemical class 0.000 description 19
239000002609 medium Substances 0.000 description 17
230000001177 retroviral effect Effects 0.000 description 17
230000004927 fusion Effects 0.000 description 16
235000018102 proteins Nutrition 0.000 description 16
102000040650 (ribonucleotides)n+m Human genes 0.000 description 14
238000010276 construction Methods 0.000 description 13
101001056475 Moloney murine leukemia virus (isolate Shinnick) Envelope glycoprotein Proteins 0.000 description 10
101150055766 cat gene Proteins 0.000 description 10
239000000047 product Substances 0.000 description 10
108091026890 Coding region Proteins 0.000 description 9
241000272534 Struthio camelus Species 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000010354 integration Effects 0.000 description 8
102100034349 Integrase Human genes 0.000 description 7
241000700605 Viruses Species 0.000 description 7
239000013592 cell lysate Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
230000003612 virological effect Effects 0.000 description 7
102000004594 DNA Polymerase I Human genes 0.000 description 6
108010017826 DNA Polymerase I Proteins 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000000349 chromosome Anatomy 0.000 description 6
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
108010087302 Viral Structural Proteins Proteins 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
229960005091 chloramphenicol Drugs 0.000 description 5
238000004520 electroporation Methods 0.000 description 5
229910052754 neon Inorganic materials 0.000 description 5
GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 5
210000004940 nucleus Anatomy 0.000 description 5
235000019333 sodium laurylsulphate Nutrition 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
230000001052 transient effect Effects 0.000 description 5
230000014616 translation Effects 0.000 description 5
101710091045 Envelope protein Proteins 0.000 description 4
108700039691 Genetic Promoter Regions Proteins 0.000 description 4
102100034353 Integrase Human genes 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
101710188315 Protein X Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000003556 assay Methods 0.000 description 4
210000000234 capsid Anatomy 0.000 description 4
241001493065 dsRNA viruses Species 0.000 description 4
108010078428 env Gene Products Proteins 0.000 description 4
239000013604 expression vector Substances 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
239000007758 minimum essential medium Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
238000013519 translation Methods 0.000 description 4
229940045145 uridine Drugs 0.000 description 4
102100022641 Coagulation factor IX Human genes 0.000 description 3
108010092160 Dactinomycin Proteins 0.000 description 3
101710177291 Gag polyprotein Proteins 0.000 description 3
229920000209 Hexadimethrine bromide Polymers 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
108020000999 Viral RNA Proteins 0.000 description 3
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
229960000640 dactinomycin Drugs 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000012139 lysis buffer Substances 0.000 description 3
235000006109 methionine Nutrition 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
238000004448 titration Methods 0.000 description 3
230000002103 transcriptional effect Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
239000008096 xylene Substances 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 2
101800001467 Envelope glycoprotein E2 Proteins 0.000 description 2
108010076282 Factor IX Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
101710159910 Movement protein Proteins 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
101710144117 Non-structural protein 4 Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
208000005074 Retroviridae Infections Diseases 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
101800001271 Surface protein Proteins 0.000 description 2
235000010724 Wisteria floribunda Nutrition 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
108091092328 cellular RNA Proteins 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000001952 enzyme assay Methods 0.000 description 2
229960004222 factor ix Drugs 0.000 description 2
238000011049 filling Methods 0.000 description 2
101150047047 gag-pol gene Proteins 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
208000009429 hemophilia B Diseases 0.000 description 2
239000012133 immunoprecipitate Substances 0.000 description 2
239000003550 marker Substances 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000006798 recombination Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000010473 stable expression Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
238000011830 transgenic mouse model Methods 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
208000007887 Alphavirus Infections Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000002585 Contractile Proteins Human genes 0.000 description 1
108010068426 Contractile Proteins Proteins 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 1
101000594820 Homo sapiens Purine nucleoside phosphorylase Proteins 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108020003217 Nuclear RNA Proteins 0.000 description 1
102000043141 Nuclear RNA Human genes 0.000 description 1
108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
108010065868 RNA polymerase SP6 Proteins 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
108010013377 Retroviridae Proteins Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000002903 Thalassemia Diseases 0.000 description 1
101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
102000013394 Troponin I Human genes 0.000 description 1
108010065729 Troponin I Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000002960 bfu-e Anatomy 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
108091092330 cytoplasmic RNA Proteins 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
108700004025 env Genes Proteins 0.000 description 1
101150030339 env gene Proteins 0.000 description 1
244000309457 enveloped RNA virus Species 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
102000043395 human ADA Human genes 0.000 description 1
229960000027 human factor ix Drugs 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
150000002742 methionines Chemical class 0.000 description 1
229960000907 methylthioninium chloride Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
238000005192 partition Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000001566 pro-viral effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
230000010415 tropism Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000006656 viral protein synthesis Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13045—Special targeting system for viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/609—Vectors comprising as targeting moiety peptide derived from defined protein from viruses positive strand RNA viruses

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002268353A 1996-10-10 1997-10-10 Vecteurs alphavirus et retrovirus Abandoned CA2268353A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
SE9603702A SE9603702D0 (sv)	1996-10-10	1996-10-10	Alfavirus-retrovirus vektorer
SE9603702-3		1996-10-10
SE9702585-2		1997-07-03
SE9702585A SE9702585D0 (sv)	1997-07-03	1997-07-03	Alfavirus-retrovirus vektorer
PCT/SE1997/001696 WO1998015636A1 (fr)	1996-10-10	1997-10-10	Vecteurs alphavirus et retrovirus

Publications (1)

Publication Number	Publication Date
CA2268353A1 true CA2268353A1 (fr)	1998-04-16

Family

ID=26662770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002268353A Abandoned CA2268353A1 (fr)	1996-10-10	1997-10-10	Vecteurs alphavirus et retrovirus

Country Status (5)

Country	Link
EP (1)	EP0932693A1 (fr)
JP (1)	JP2001501483A (fr)
AU (1)	AU729690B2 (fr)
CA (1)	CA2268353A1 (fr)
WO (1)	WO1998015636A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
US6451592B1 (en)	1996-04-05	2002-09-17	Chiron Corporation	Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
GB9720465D0 (en)	1997-09-25	1997-11-26	Oxford Biomedica Ltd	Dual-virus vectors
GB2344592B (en) *	1997-09-25	2002-09-11	Oxford Biomedica Ltd	Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site
US8647864B2 (en)	1999-04-14	2014-02-11	Novartis Ag	Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DK1196637T3 (da)	1999-07-27	2007-07-30	Adnexus Therapeutics Inc	Peptidacceptor-ligeringsmetoder
CA2388337C (fr)	1999-10-22	2013-01-08	Aventis Pasteur Limited	Procede visant a provoquer et/ou stimuler une reponse immunitaire aux antigenes tumoraux
DK1282702T3 (da)	2000-05-10	2007-04-02	Sanofi Pasteur Ltd	Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US6767699B2 (en)	2000-05-31	2004-07-27	Chiron Corporation	Method for the quantitation of alphavirus replicon particles
US9738907B2 (en)	2002-02-01	2017-08-22	Oxford Biomedica (Uk) Limited	Viral vector
WO2005026316A2 (fr) *	2003-09-15	2005-03-24	Bioption Ab	Vaccins contre les arbovirus
ES2292271B1 (es) *	2004-05-20	2009-02-16	Proyecto De Biomedicina Cima, S.L.	Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
CN113604505A (zh) *	2021-08-11	2021-11-05	华农（肇庆）生物产业技术研究院有限公司	pSFV-p32病毒样颗粒及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9003978D0 (sv) *	1990-12-13	1990-12-13	Henrik Garoff	Dna expressionssystem baserade paa ett virus replikon
SE9401709D0 (sv) *	1994-05-18	1994-05-18	Mathilda Sjoeberg	Improved alphavirus vectors for expression of heterologous DNA
AU4594996A (en) *	1994-11-30	1996-06-19	Chiron Viagene, Inc.	Recombinant alphavirus vectors

1997
- 1997-10-10 EP EP97945152A patent/EP0932693A1/fr not_active Withdrawn
- 1997-10-10 AU AU46422/97A patent/AU729690B2/en not_active Ceased
- 1997-10-10 JP JP10517462A patent/JP2001501483A/ja active Pending
- 1997-10-10 WO PCT/SE1997/001696 patent/WO1998015636A1/fr not_active Ceased
- 1997-10-10 CA CA002268353A patent/CA2268353A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
AU729690B2 (en)	2001-02-08
AU4642297A (en)	1998-05-05
EP0932693A1 (fr)	1999-08-04
JP2001501483A (ja)	2001-02-06
WO1998015636A1 (fr)	1998-04-16

Legal Events

Date	Code	Title	Description
2002-10-09	EEER	Examination request
2004-10-12	FZDE	Discontinued

Publication	Publication Date	Title
US6165782A (en)	2000-12-26	Method and means for producing high titer, safe, recombinant lentivirus vectors
Wagner et al.	2000	Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors
US5886166A (en)	1999-03-23	Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector
US4861719A (en)	1989-08-29	DNA constructs for retrovirus packaging cell lines
RU2749717C2 (ru)	2021-06-16	Способ временной трансфекции для продуцирования ретровируса
AU729690B2 (en)	2001-02-08	Alphavirus-retrovirus vectors
Li et al.	1996	Production of infectious recombinant Moloney murine leukemia virus particles in BHK cells using Semliki Forest virus-derived RNA expression vectors.
WO1998015636A9 (fr)	1998-06-11	Vecteurs alphavirus et retrovirus
Gilboa	1986	Retrovirus vectors and their uses in molecular biology
JP2000500013A (ja)	2000-01-11	プソイドタイプのレトロウイルスを産生する安定パッケージング細胞株
JP2000501286A (ja)	2000-02-08	レトロウイルスベクターの宿主適応
AU741764B2 (en)	2001-12-06	Retroviral vector particles produced in a baculovirus expression system
US20020042136A1 (en)	2002-04-11	Retroviral vectors comprising an enhanced 3' transcription termination structure
US7981656B2 (en)	2011-07-19	Pseudotyped retrovirus with modified ebola glycoprotein
IL116216A (en)	2007-02-11	Eukaryotic cell lineages for recombinant viral retroviral RNA storage, using trans-expression vectors used to complete the trans
US20230151388A1 (en)	2023-05-18	Modified vectors for production of retrovirus
Garoff et al.	1998	Alphavirus-Retrovirus Vectors
Armentano	1986	MAPPING AND FUNCTIONAL ANALYSIS OF THE PACKAGING SIGNAL OF MOLONEY MURINE LEUKEMIA VIRUS (RETROVIRAL VECTORS)
JPWO1996038545A1 (ja)	1998-07-21	組み換えレトロウィルス産生細胞
GB2544891A (en)	2017-05-31	Transient transfection method for retroviral production